RECURSION PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
RECURSION PHARMACEUTICALS, INC. (RXRX) had Debt Securities, Available-for-sale, Amortized Cost of $404.61 million as of 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-02-27
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $404.61M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $401.85M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $400.34M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $399.91M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-12-31 | $404.61M 10-K · filed 2023-02-27 |
| 2022-09-30 | $401.85M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $400.34M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $399.91M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $399.50M 10-K · filed 2023-02-27 |
| 2021-09-30 | $405.91M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |